Home › Research › Prevention and risk
Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension: an open-label, blinded-endpoint, cluster-randomized trial
He J, Zhao C, Zhong S, Ouyang N, Sun G, Qiao L, et al.. Nature Medicine, 2025-04-21
Topic: Risk, prevention and care in population studies
Plain-language summary
Dementia is a leading cause of death and disability worldwide. Here we tested the effectiveness of blood pressure (BP) reduction on the risk of all-cause dementia among 33,995 individuals aged ≥40 years with uncontrolled hypertension in rural China. We randomly assigned 163 villages to a non-physician community healthcare provider-led intervention and 163 villages to usual care. In the intervention group, trained non-physician community healthcare providers initiated and titrated antihypertensive medications according to a simple stepped-care protocol to achieve a systolic BP goal of <130 mm Hg and a diastolic BP goal of <80 mm Hg, with supervision from primary care physicians. Over 48 months, the net reduction in systolic BP was 22.0 mm Hg (95% confidence interval (CI) 20.6 to 23.4; P < 0.0001) and that in diastolic BP was 9.3 mm Hg (95% CI 8.7 to 10.0; P < 0.0001) in the intervention group compared to usual care. The primary outcome of all-cause dementia was significantly lower in the intervention group than in the usual care group (risk ratio: 0.85; 95% CI 0.76 to 0.95; P = 0.0035). Additionally, serious adverse events occurred less frequently in the intervention group (risk ratio: 0.94; 95% CI 0.91 to 0.98; P = 0.0006). This cluster-randomized trial indicates that intensive BP reduction is effective in lowering the risk of all-cause dementia in patients with hypertension. ClinicalTrials.gov: NCT03527719 .
What this study adds
Evidence grade: High
The record lists 33,995 participants. In this cluster-randomized trial of 33,995 people in rural China with uncontrolled hypertension, an intensive blood pressure reduction programme significantly lowered the risk of all-cause dementia compared with usual care. Reported effect size: All-cause dementia RR 0.85 (95% CI 0.76-0.95).
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
He, J., Zhao, C., Zhong, S., Ouyang, N., Sun, G., Qiao, L., et al. (2025). Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension: an open-label, blinded-endpoint, cluster-randomized trial. Nature Medicine. https://doi.org/10.1038/s41591-025-03616-8
Vancouver
He J, Zhao C, Zhong S, Ouyang N, Sun G, Qiao L, et al. Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension: an open-label, blinded-endpoint, cluster-randomized trial. Nature Medicine. 2025. doi:10.1038/s41591-025-03616-8. PMID: 40258956.
BibTeX
@article{he2025-40258956,
author = {He, J. and Zhao, C. and Zhong, S. and Ouyang, N. and Sun, G. and Qiao, L. and others},
title = {{Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension: an open-label, blinded-endpoint, cluster-randomized trial}},
journal = {Nature Medicine},
year = {2025},
doi = {10.1038/s41591-025-03616-8},
pmid = {40258956},
url = {https://doi.org/10.1038/s41591-025-03616-8}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Over 48 months, the net reduction in systolic BP was 22.0 mm Hg (95% confidence interval (CI) 20.6 to 23.4; P < 0.0001) and that in diastolic BP was 9.3 mm Hg (95% CI 8.7 to 10.0; P < 0.0001) in the intervention group compared to usual care.
- The primary outcome of all-cause dementia was significantly lower in the intervention group than in the usual care group (risk ratio: 0.85; 95% CI 0.76 to 0.95; P = 0.0035).
- This cluster-randomized trial indicates that intensive BP reduction is effective in lowering the risk of all-cause dementia in patients with hypertension.
Why it matters
In this cluster-randomized trial of 33,995 people in rural China with uncontrolled hypertension, an intensive blood pressure reduction programme significantly lowered the risk of all-cause dementia compared with usual care. It indicates that intensive blood pressure control can reduce dementia risk in people with hypertension, but it does not address treating or curing dementia once it has developed.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designRCT
- Participants33,995
- Effect sizeAll-cause dementia RR 0.85 (95% CI 0.76-0.95)
- Evidence strengthHigh
Limitations
Open-label design with blinded endpoint adjudication; rural Chinese setting with very high baseline blood pressure; four-year horizon.
How this study scored 82/100
Published in a top-tier journal, and it is a randomized controlled trial. We have no data on free to read, so that was left out: it earned 80 of the 98 points we could judge it on, which is 82 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (Nature Medicine) |
| Journal's citation record | 4 / 4 | Nature Medicine: journal h-index 763 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 33,995 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 4 / 7 | Cited 51 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 17.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 5 / 6 | Cited 33.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 3 / 4 | Cited 51 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Yingxian Sun: h-index 46 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | The University of Texas Southwestern Medical Center: institution h-index 1,356 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 9 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40258956) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 80 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 80 of the 98 points we could judge it on is 82 out of 100. |
| Total | 82 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in Prevention and risk from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.